SIPI-6398

N/A

Report date: 2024/06/04 16:20:28
NME

Base Information

Drug NameSIPI-6398
Drug Alias NameSIPI-6398SIPI6398ZZ-6398
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D3 receptor antagonistsDopamine D2 receptor antagonistsSerotonin 1a (5-HT1a) receptor antagonists +[4] 
TargetsDopamine D3 receptorDopamine D2 receptorSerotonin 1a (5-HT1a) receptor +[4] 
Therapy Area/IndicationsSchizophreniaDepressive Disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Zhongze Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Zhongze Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSchizophreniaDepressive Disorder
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A